Everolimus for Lymphoblastic Leukemia (ENCERT Trial)

"Currently, the trial is accepting patients at four locations: New york, Cincinnati and Atlanta among others. To reduce travel demands associated with participation in this study, it's important to register at a medical center close to you."

"Everolimus is a commonly prescribed treatment for leukemia and has shown to be successful in mitigating refractory advanced renal cell carcinoma, prostate cancer, and lung cancers."

"Affirmative. The information posted on clinicaltrials.gov reveals that this research endeavour, which was first introduced on July 24th 2018 is currently searching for participants. A total of 15 individuals are expected to enrol from across 4 distinct centres."

"Everolimus was first studied in 1997 at the City of Hope Comprehensive Cancer Center. To date, 1758 trials have been completed and 1082 are actively recruiting new participants. Of these active studies, many are based in New york City."

"This medical trial is limited to those between the ages of 2 and 29. There are 982 studies for minors, while elder patients have access to 3312 clinical trials."

"The safety of Everolimus is rated a 1 because it has yet to go through the necessary trials for full efficacy and safety testing."

"As indicated on clinicaltrials.gov, this medical experiment has been actively seeking participants since its initial posting date of July 24th 2018 and was last modified on August 18th 2022."

"Recruitment for this trial is actively seeking 15 individuals suffering from leukemia ranging in age between 2 and 29. Eligibility requirements are outlined as follows: CNS status may be accepted if other sites of malignancy exist, performance score must meet either Karnofsky or Lansky standards (depending on subject's age), patients rendered immobile due to paralysis will still qualify as ambulatory, histology confirming diagnosis at the onset or relapse, 1 year old minimum with 30 years being the upper limit. Lymphoma sufferers also eligible."